Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma: Results of a phase II trial
- 31 March 2006
- journal article
- research article
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 30 (3), 357-363
- https://doi.org/10.1016/s0399-8320(06)73188-8
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II studyAnnals of Oncology, 2003
- Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II studyBritish Journal of Cancer, 2002
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002
- A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaCancer, 2001
- A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinomaCancer, 2000
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnnals of Oncology, 1996
- The national cancer data base report on pancreatic cancerCancer, 1995
- Chemotherapy prolongs survival in inoperable pancreatic carcinomaBritish Journal of Surgery, 1994